Skip to main
CBLL

Ceribell Inc (CBLL) Stock Forecast & Price Target

Ceribell Inc (CBLL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CeriBell is a medical technology company with a strong focus on neurological conditions. The company's proprietary Ceribell System utilizes advanced AI-powered algorithms to enable rapid diagnosis and continuous monitoring of patients with neurological conditions. The company has already gained significant commercial traction and is actively investing in its salesforce and pipeline to drive near-term and long-term growth. With a healthy financial profile and a strong focus on innovation, CeriBell is well-positioned for success in the growing medical technology market.

Bears say

CeriBell is a medical technology company with a negative outlook. Despite receiving FDA approval to expand its on-label indication to pediatrics and neonates, its profitability may be affected by its high expenses and ongoing IP litigation costs. Additionally, there is uncertainty regarding the company's timeline and revenue level to reach cash-flow breakeven. While there may be potential for growth with its new offerings and initiatives, the company faces competition in the market and potential challenges with tariffs on imports from China.

Ceribell Inc (CBLL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ceribell Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ceribell Inc (CBLL) Forecast

Analysts have given Ceribell Inc (CBLL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Ceribell Inc (CBLL) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ceribell Inc (CBLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.